Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR9.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR2.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR1.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR4.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR3.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR5.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR8.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR7.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR6.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR22.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR23.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR13.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR24.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR17.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR19.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR15.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR27.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR12.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR14.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR25.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR16.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR26.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR10.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR18.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR20.htm
EX-10.1 - EXHIBIT 10.1 - HEALTH DISCOVERY CORPex10-1.htm
EX-32.1 - EXHIBIT 32.1 - HEALTH DISCOVERY CORPex32-1.htm
EX-10.2 - EXHIBIT 10.2 - HEALTH DISCOVERY CORPex10-2.htm
EX-31.1 - EXHIBIT 31.1 - HEALTH DISCOVERY CORPex31-1.htm
10-Q - FORM 10-Q - HEALTH DISCOVERY CORPt74989_10q.htm
XML - IDEA: XBRL DOCUMENT - HEALTH DISCOVERY CORPR21.htm
v2.4.0.6
STOCKHOLDERS' EQUITY
9 Months Ended
Sep. 30, 2012
Stockholders Equity Note [Abstract]  
STOCKHOLDERS' EQUITY
Note F – STOCKHOLDERS’ EQUITY
 
Series B Preferred Stock
 
During the first quarter of 2009 the Board of Directors authorized the designation of Series B Preferred Stock. The number of shares originally constituting the Series B Preferred Stock was 13,750,000; however, during the fourth quarter of 2009 the Board of Directors authorized the increase in the number of shares constituting the Series B Preferred Stock to 20,625,000. The Company sold to individual investors a total of 19,402,675 shares of Series B Preferred Stock for $1,490,015, net of associated expenses, in 2009. The Series B Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies.
 
The Series B Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series B Preferred Stock must be converted into Common Stock of the Company upon the demand by the Company after the fifth anniversary of the date of issuance.
 
The Series B Preferred Stock accrues dividends at the rate of 10% of the Series B Original Issue Price per year, which shall be satisfied by the fifth anniversary of the issuance of such shares of the Series B Preferred Stock (the “Original Issue Date”) by the Company’s issuance of the number of shares of Common Stock equal to such accrued dividends divided by the average closing price of the Company’s Common Stock as reported on the Over-the-Counter-Bulletin Board or other exchange on which the Company’s Common Stock trades during the prior ten business days or by the payment of cash, as the Company may determine in its sole discretion. Dividends have been accrued for the Series B Preferred Stock in the amount of $420,580 as of September 30, 2012 and $316,064 as of December 31, 2011.
 
Subject to the limitations set forth in the Amended and Restated Articles of Amendment to Articles of Incorporation and applicable law, as long as the Series B Preferred Stock remain outstanding, the Company is required to pay the holders of the Series B Preferred Stock a special dividend equal to 15% of Company Net Revenue collected beginning with the Original Issue Date and ending on the date the Series B Preferred Stock cease to be outstanding (the “Cash Bonus”). Company Net Revenue will include, but not be limited to, revenue derived from development fees, license fees and royalties paid to the Company and revenue collected as a result of the sale of any asset of the Company or distributions from SVM Capital, LLC (each a “Revenue Contract”), reduced by the amount of any out-of-pocket costs or expenses that are directly related to obtaining, negotiating or documenting the Revenue Contracts and the performance of such Revenue Contracts, but shall not include the proceeds of any capital infusions from the exercise of outstanding options or warrants or as a result of any capital raise undertaken by the Company. At any time following the Original Issue Date, the Company may satisfy the special dividend right in its entirety if the aggregate payments made to the Series B Holders are equal to that value which provides an internal annual rate of return of twenty percent (20%) on the Series B Preferred Stock. The maximum Cash Bonus to be paid each year shall be the aggregate Series B Original Issue Price, and no amounts in excess of such amount shall accrue or carry-over to subsequent years. Dividends in the amount of $370,899 and $21,018 have been accrued for Series B Preferred Stock special dividend as of September 30, 2012 and December 31, 2011, respectfully. The Company paid $185,450, which represents half of the special dividend owed, in October 2012 and intends to pay the balance of the special dividend, which is an additional $185,450, owed to the Series B Shareholders before the end of 2012.
 
However, no dividend payment will be made if, after the payment of such dividend, the Company would not be able to pay its debts as they become due in the usual course of business, or the Company’s total assets would be less than the sum of its total liabilities plus the amount that would be needed, if the Company were to be dissolved, to satisfy the preferential rights upon the dissolution to shareholders whose preferential rights are superior to those receiving the dividend.